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Summary
Objective: The aim of this study was to define the relative regulation of matrix metalloproteinase-3 (MMP-3), and tissue
inhibitor of metalloproteinases-1 (TIMP-1), in chondrocytes and synovium in experimental osteoarthritis (EOA).
Methods: Partial-meniscectomized (PM) rabbits, surgical sham controls (SH), and normal non-surgical controls (N)
were killed at times corresponding to early degenerative lesions (4 weeks) and increasingly progressive stages of EOA
at 8 and 12 weeks post-PM. MMP-3 activity was measured in conditioned media from chondrocytes and synovium using
a peptide cleavage assay with substance P (SP) as the substrate. TIMP-1 was quantitated using an enzyme-linked
immunosorbent assay (ELISA).
Results: Early degenerative lesions (4 weeks post-PM) were characterized by inflammatory responses in the synovium
accompanied by a significant rise of MMP-3 activity in synovial cultures (P Q 0.05). At 8 weeks there was no discernible
inflammation, and MMP-3 activity in EOA synovial cultures was comparable to that in the controls; this was followed
by a second increase in MMP-3 activity in EOA samples at 12 weeks. MMP-3 activity was significantly elevated in
EOA chondrocyte cultures at 8 weeks post-PM relative to N controls, corresponding to the most destructive phase
of EOA, but not in the early phase (4 weeks) or ‘late’ degenerative phase (12 weeks). Medium derived from chondrocytes
contained little or no TIMP-1. Synovia secreted relatively higher amounts of TIMP-1, and this was elevated at 8 weeks
post-PM relative to the SH controls. The majority (approximately 90%) of MMP-3 activity could be inhibited
using recombinant TIMP-1 or a hydroxamate MMP inhibitor. Complete inhibition was achieved with EDTA or
1,10 phenanthroline.
Conclusion: Together, these data indicate that in EOA, MMP-3 is initially upregulated in the synovium which may
play a pivotal role in the pathogenesis of cartilage lesions. In contrast, chondrocyte-derived MMP-3 is upregulated
in the later phases of EOA, contributing further to progression of cartilage lesions.
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Introduction
The progressive destruction of articular cartilage
is a salient feature of joint pathophysiology in
osteoarthritis (OA). The destructive cartilage
matrix alterations in OA are thought to be due to
the action of matrix-degrading proteinases, some
belonging to the matrix metalloproteinase (MMP)
family [1–5], and some to other classes, such as the
lysosomal cathepsins [6–8], and serine type
proteinases such as plasmin [9, 10]. Several studies
using human cartilage from OA patients, or tissue
derived from animals with experimental OA (EOA)
have suggested a major contribution to cartilage
degradation by MMPs [3–5, 11–14]. Collagenase-1
(MMP-1) and collagenase-2 (MMP-8) are impli-
cated in the initial proteolytic cleavage of native
collagen followed by gelatinolytic activity that
leads to complete degradation of collagen [15–18].
Stromelysin (MMP-3) can degrade aggrecan mol-
ecules at a defined site between the G1 and the G2
globular domains of the core protein correspond-
ing to the sequence FMDIPEN 4 FFGVG [19],
although other members of the MMP family such
as MMP-1 or MMP-8 can also produce this
cleavage [20, 21]. MMP-3 can cleave a variety of
other matrix components and has been suggested
to play a role in the in situ degradation of cartilage
link protein [22].
Recently, it was demonstrated that collagenase-3
(MMP-13), previously only known to be expressed
in a carcinoma [23], was upregulated in human OA
cartilage [14, 24]. MMP-13, like MMP-1, degrades
type II collagen fibers, but appears to be more
active than MMP-1 [24]. MMP-13 can also cleave
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cartilage aggrecan at the MMP cleavage site in the
interglobular domain [25, 26].
Several studies have suggested that there may be
an over-expression of MMPs relative to the tissue
inhibitors of metalloproteinases (TIMPs) in OA
joints [3, 27]. Measurement of MMP-1, MMP-3 and
TIMP in synovial fluid (SF) samples of OA patients
revealed elevated concentrations of MMPs in the
SF relative to TIMP [13]. The higher concen-
trations of MMPs relative to TIMP would favor
cartilage matrix catabolism.
It has been shown that some aggrecan fragments
isolated from human SF contain an N-terminus
corresponding to a cleavage other than that
created by the typical MMP cleavage in the G1–G2
interglobular domain of aggrecan. An enzyme
termed aggrecanase, was proposed to be respon-
sible for the cleavage leading to creation of these
aggrecan fragments with N-termini ending in the
sequence ARGSV [28]; however, MMP-8 was shown
to be capable of producing this cleavage also [29].
We have previously reported that pro-
stromelysin and pro-collagenase genes are
upregulated in chondrocytes from the knees of
rabbits with EOA; pro-stromelysin mRNA was
upregulated early in experimental disease and
increased significantly as EOA pathology pro-
gressed. Pro-collagenase mRNA upregulation
followed a similar pattern but the level of
expression was not as high as pro-stromelysin
mRNA [4]. In the present study we use a peptide
substrate, substance P [SP], to quantitate the
MMP-3 activity secreted from EOA chondrocytes
and synovium at time points in EOA representing
early degenerative lesions [4 weeks post partial
menisectomy (PM)], and progressive stages of
disease (8 weeks and 12 weeks). The temporal
sequence of the upregulation of MMP-3 activity
and of TIMP-1 in chondrocytes and synovium of
EOA rabbits is presented and its significance
discussed in relation to possible mechanisms of
pathogenesis.
Methods
induction of eoa
EOA was induced in both knees of female New
Zealand white rabbits (specific pathogen-free, 6–8
weeks old, 1.8–2.3 kg; Hazelton Laboratories,
Denver, PA, U.S.A.) using the technique of PM as
described [30]. Sham operated (SH) and non-
operated (N) rabbits served as controls. A total of
87 rabbits were used in the study over a period of
2 years. These were divided up into groups that
were killed at 4 weeks (N = 9 each of N, SH, PM),
8 weeks (N = 14 each group), and 12 weeks (N = 6
each group) post-surgery. Joint pathology was
recorded at the time of death. Typical EOA
cartilage pathology at 4 weeks post-surgery
consisted mainly of small osteophytes and
moderate pitting. At 8 weeks, full-thickness
cartilage erosions were present with larger
marginal osteophytes; progression to 12 weeks was
accompanied by increasing ulceration. The patho-
logical changes encountered in this EOA model
have been previously described in detail [30].
assessment of synovial pathology
Synovia were fixed in 4% paraformaldehyde
overnight and embedded in paraffin by standard
procedures. Six micron sections were cut, de-
paraffinized, stained with hematoxylin, examined
under the light microscope and photographed.
tissue culture methods
Reagents and media
All enzymes used for cell dissociation were from
Worthington Biochemical Corporation, Freehold,
NJ, U.S.A.; tissue culture media and serum were
obtained from Gibco BRL, Grand Island, NY,
U.S.A.
Cartilage was shaved under sterile conditions
and pooled from both legs of each rabbit.
Chondrocytes were liberated from matrix by
enzymatic digestion with trypsin and collagenase.
All details pertaining to the cell dissociation were
as previously described [8]. Liberated chondro-
cytes were cultured in suspension in Ham’s F12
medium containing antibiotics and 0.2% lactalbu-
min hydrolysate. Synovia were pooled from both
legs of each rabbit and cultured without cell
dissociation. Details regarding tissue culture
methods were as described [8].
measurement of mmp activity in culture
supernatants
Metalloproteinase activity was quantitated
using the SP assay [31, 32]. In this assay, SP is used
as substrate followed by separation of proteolytic
cleavage products by high-pressure liquid chroma-
tography (HPLC) on a reverse-phase column (C-18)
using acetonitrile gradient with detection of the
peptide fragments at 215 nm. Various quantities of
SP (1–10 mg) were applied to the HPLC column and
eluted. A standard curve was constructed by
plotting the area under the SP peak versus the
quantity of SP applied to the column. The data was
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fitted to a first-order regression plot (r2 = 0.9318).
The MMP-3 activity in the test samples were
calculated from the area under the peak of the SP
remaining after the incubation, by reference to the
standard curve and converted into micrograms of
SP cleaved per hour at 37 ° C. One unit of enzyme
activity is defined as that which degrades 1 mg of
SP per hour at 37° C, producing the peptide
fragment SP7–11.
We modified the original method for culture
medium as follows. To avoid proteolysis of SP by
nonspecific proteases that may be present in the
medium, we performed the assays in the presence
of a cocktail of protease inhibitors that would
inhibit all classes of proteolytic activity except
metal-dependent enzymes. The medium to be
assayed (50 ml) was diluted in 2 · assay buffer
(50 mm Tris–HCl pH 7.5, 10 mm CaCl2, 0.04%
sodium azide, 0.1% Brij-35, 2 mm phenylmethyl
sulfonyl fluoride, 2 mm iodoacetic acid, 5 mg/ml
pepstatin, 5 mm E64). Five micrograms of SP was
added and the sample incubated for 18 h at 37° C.
The reaction was stopped with addition of ethylene
glycol-bis (b-aminoethyl ether) N,N,N'N'-tetra-
acetic acid (EGTA) to final concentration of 20 mm
and 50 ml aliquot of the sample was analyzed by
reverse-phase HPLC. Total enzyme (ac-
tive + latent) was assayed after activation with
0.1 mm p-aminophenyl mercuric acetate (APMA)
for 4 h at 37° C. Control samples were incubated
with buffer containing 10 mm EDTA instead of
CaCl2. When recombinant human MMP-3 (rMMP-
3) was added into medium it produced the expected
cleavage products in this system.
measurement of timp-1
TIMP-1 was measured with an enzyme-linked
immunosorbent assay (ELISA) as described
[33, 34]. This ELISA measured only free TIMP-1
and not TIMP-1 complexed to MMPs.
enzyme inhibition studies
Inhibition of metalloproteinase activity was
assessed using the following inhibitors. Recombi-
nant rabbit TIMP (rTIMP), and a hydroxamic acid
MMP inhibitor with broad specificity against all
members of MMP family, BB2116. This inhibitor
was a gift from Dr Allen Drummond of British
Biotech Pharmaceuticals Limited, Oxford, U.K.
The IC50 of BB2116 versus MMP-3 is 30 nm (data
from British Biotech).
For quantitation of percent inhibition produced,
the culture media were diluted with 2 · assay
buffer followed by preincubation with the inhibitor
under study for 15 min at 23° C before the addition
of SP. The percent inhibition was calculated
relative to that produced with 10 mm EDTA
(100%). The final concentrations of the inhibitors
were, BB2116, 2 mm; rTIMP, 10 mg/ml.
recombinant proteins and reagents
Recombinant rabbit TIMP (rTIMP) was pro-
duced in by Celltech Ltd, as described [35].
Recombinant human MMP-3 (rMMP-3) was ex-
pressed in a mammalian expression system and
purified as previously reported [36]. SP and SP7–11
were purchased from Sigma (St Louis, MO, U.S.A.).
Tissue culture media and solutions were obtained
from Gibco (Grand Island, NY, U.S.A.). All other
chemicals and HPLC solvents were of the highest
purity available obtained from Sigma, or Fisher
Scientific (Pittsburgh, PA, U.S.A.). Other synthetic
peptides were custom made by Genemed Labora-
tories, San Francisco, CA, U.S.A.
statistical analyses
The significance of the data was determined
using Student’s two-tailed t-test with a significance
level at P Q 0.05. Statistical parameters of kurtosis
and skewness were used in order to determine
whether the data were normally distributed. For
normal distribution the values of kurtosis and
skewness were between - 2 to + 2. Sample size
analysis was performed to determine the adequacy
of group size. The parameters used for sample size
determination were, P = 0.05 and power = 0.9.
Results
Fig. 1 shows light microscope photographs of
6 mm stained synovial sections taken at 4 weeks
post-PM [Fig. 1(a)], similar sections from SH
[Fig. 1(b)] and N [Fig. 1(c)] rabbits are shown. For
comparison, a synovial section from an 8-week
post-PM rabbit is shown (d). Examination of the
sections revealed a low degree of cellular
infiltration at 4-weeks post-PM; no evidence of
inflammation could be discerned in the controls at
4 weeks, or in the EOA synovia sampled at 8 weeks
(d) or 12 weeks (not shown).
The SP degradation HPLC assay was previously
used for measurement of activity of rMMP-3. We
modified the HPLC procedure so that the peptides
were separated with a gradient of acetonitrile
rather than under isocratic elution; this led to the
separation of the SP peak and the main cleavage
product produced by MMP-3 so as to minimize
interference from other medium components.
14.8 22.2
(a)
SP
14.8 22.2
(b)
SP
Time (min)Time (min)
SP 7-11
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Fig. 1. Six micron paraffin sections of synovium from (a) 4 weeks post-partial meniscectomized rabbit (PM), (b) 4 weeks
sham-operated (SH), (c) 4 weeks normal (N), and (d) 8 weeks post-PM EOA rabbits were stained with hematoxylin and
photographed. Original magnification, · 100).
Under these conditions SP had a retention time of
approximately 17.1 min [Fig. 2(a)], and SP7–11 eluted
with a retention time of 18.6 min [Fig. 2(b)]. The
fragment SP1–6 had a low retention, and a very low
absorbance relative to SP or SP7–11. The production
of fragment SP7–11 was confirmed with a synthetic
peptide corresponding to SP7–11 sequence which
eluted at the same position in the profile.
In order to validate the SP cleavage assay for
crude culture medium we first determined the SP
degrading activity of conditioned media in the
presence and absence of divalent metal ions. We
confirmed that SP degrading activity was only
detectable in the presence of calcium ions.
Addition of metal chelators EDTA, EGTA, or
1,10-phenanthroline to the conditioned medium
abolished all SP degrading activity. When rMMP-3
was added to the medium that had no detectable
TIMP, full activity was recovered relative to buffer
control. The fragment SP7–11 could be seen in the
HPLC profile. Fragment SP1–6 had a low retention
time it was not detected in medium because of
co-elution with other medium components; how-
ever, it was detectable in buffer.
We also used a peptide with the sequence
MDIPENFFGVG containing the putative MMP
recognition sequence found in aggrecan. As
expected, this peptide was cleaved by rMMP-3 into
two fragments, and also by the MMP activity in the
media. The medium activity towards this peptide
was also inhibited with metal chelators (data not
shown). Because MMP-1 also cleaves the aggrecan
peptide [26], we used SP so as to minimize
interference of MMP-1 activity in the assay.
Fig. 3 shows the means ( 2 s.d.) of MMP-3
activity expressed as SP cleavage units, in media
derived from synovia obtained from rabbits of the
three experimental groups, at three sequential
time points (4 weeks, 8 weeks and 12 weeks
post-PM) in EOA. The mean activity in the PM
group was significantly higher compared with the
N or SH group at 4 weeks post-PM. At 8 weeks,
Fig. 2. An HPLC chromatogram showing the elution
profile of SP before (a), and after (b) cleavage by
recombinant human MMP-3.
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Fig. 3. MMP-3 activity (active and total) was measured
in synovial conditioned media (SCM) from non-operated
controls (Nq), sham-surgical controls (SH;), and
partial-meniscectomized (PMQ) rabbits at various time
points in EOA. Group means (error bar = s.d.) are shown;
n is the number of rabbits in each group. NS = not
statistically significant.
Fig. 4. MMP-3 activity (active and total) was measured
in chondrocyte conditioned media (CCM) from non-
operated controls (Nq), sham-surgical controls (SH;),
and partial-meniscectomized (PMQ) rabbits at various
time points in EOA. Group means (error bar = s.d.) are
shown; n is the number of rabbits in each group.
NS = not statistically significant.
activity levels in the PM group declined so that
there was not a significant difference in the three
groups at this time point. At 12 weeks post-surgery,
the mean activity in OA-derived synovial-
conditioned media (SCM) was significantly higher
than in SH group, but not compared with N group.
Activation of latent enzyme in the media produced
small increments in the activities measured in all
cases and did not impact the statistical signifi-
cance of the data.
Fig. 4 shows the mean and standard deviations
( 2 s.d.) of MMP-3 activity, in conditioned media
from EOA chondrocytes, at the same time points as
above, before and after activation of the latent
MMP-3. Comparison of the means by Student’s
two-tailed t-test revealed that there was no
significant difference in active or total metallo-
proteinase activity in the media at 4 weeks
post-PM when compared with either N or SH
chondrocyte-derived media. However, at 8 weeks
post-PM there was a significantly higher active
and total SP degrading activity in the PM
chondrocyte-conditioned (CCM) media compared
with media obtained from age-matched normals
(N) (P Q 0.05). The mean activity in sham-derived
CCM was not significantly lower than PM. At 12
weeks post-PM the mean enzyme levels (active and
total) were not significantly different between the
groups. It is of note, however, that at 12 weeks N
chondrocytes produced higher amounts of enzyme
than at 4 or 8 weeks.
A few CCMs contained free detectable TIMP-1 at
very low levels. By comparison SCMs contained
relatively high concentrations of free immuno-
reactive TIMP (Fig. 5). The mean concentration of
free TIMP in the media was not significantly
different in the three groups at either 4 or 12 weeks
post-PM. At 8 weeks, TIMP was significantly
higher in EOA-derived media relative to SH media
only. Interestingly, there was an age-related
Fig. 5. TIMP-1 was quantitated in synovial conditioned
media from non-operated controls (Nq), sham-surgical
controls (SH;), and partial-meniscectomized (PMQ)
rabbits at various time points in EOA. Group means
(error bar = s.d.) are shown; n is the number of rabbits
in each group. NS = not statistically significant.
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Table I
Inhibition of metalloproteinase activity in chondrocyte-conditioned media (CCM)
and synovial-conditioned media (SCM) by various MMP inhibitors
EDTA (10 mm) BB2116 (2 mm) rTIMP (10 mg/ml)
rMMP-3 (N = 3) 100 94.4 2 11.2 95.6 2 5.1
CCM (N = 4) 100 86.9 2 6.6 85.3 2 6.2
SCM (N = 4) 100 99.9 2 9.3 86.0 2 11.5
Four different media obtained at 7 week post!PM were evaluated with MMP inhibitors[ The
average percent inhibition " 2 S[D[# is shown[
decline in TIMP secretion noted in the normal
control group. TIMP was significantly higher in
the younger rabbits (at 4 weeks) relative to 8 weeks
(P Q 0.05). The decrease in secretion leveled off
between the 8th and the 12th weeks such that no
further difference was noted between 8 and 12
weeks. A similar significant decline in TIMP was
seen in the SH group between the 4 and 8 week
time periods, but in the latter there was higher
TIMP secretion at 12 weeks. The TIMP secreted by
the PM group did not decline significantly with
time.
Table I shows the mean of percentage inhibition
of MMP-3 activity in conditioned media of
chondrocytes and synovia from EOA rabbits
produced by specific MMP inhibitors. Inhibition
was 100% with metal chelator EDTA. A broad-
spectrum MMP inhibitor BB2116, produced 86.9%
inhibition in CCMs and 99.9% inhibition in SCMs;
rTIMP produced 85.3% inhibition of activity in
CCMs and 86% inhibition in SCMs. The inhibition
achieved with either BB2116 or rTIMP with
rMMP-3 was close to 95%.
Discussion
In OA, the degradation of cartilage leading to
the formation of lesions is likely brought about by
the action of multiple matrix degrading proteases.
These proteases may be synthesized and activated/
deactivated at different times in the emergence of
OA pathology according to the environmental
signals and stimuli in the pathogenesis
mechanism.
In a previous study we demonstrated up-
regulation of both pro-collagenase and pro-
stromelysin mRNAs in rabbit OA chondrocytes [4].
The expression of both pro-MMP-3 and pro-MMP-1
mRNAs in the synovium was later confirmed
(unpublished data). Accordingly, in order to
exclude MMP-1 activity in this investigation we
evaluated recombinant human MMP-1 (a gift from
G.D. Searle and Company, St Louis, MO, U.S.A.)
and demonstrated that it did not cleave SP (data
not shown).
In the present study we showed that conditioned
media from chondrocytes and synovial tissue
obtained from EOA rabbit knees contains elevated
levels of an MMP that degrades SP. The activity
was inhibited with rTIMP, and also with a
hydroxamic acid MMP inhibitor BB2116, this
being consistent with MMP-3 activity. However,
recombinant MMP-13 can degrade SP (data not
shown); it is therefore possible that some of the
activity detected may be due to the presence of
MMP-13 in the media. It is not possible with the
present techniques and substrates to ascertain
what, if any, the contribution to SP degradation in
the assay due to MMP-13 may be. Purification and
quantitation of each MMP activity in the medium
is necessary in order to answer this question.
In this respect it is worth noting that the total
MMP SP degrading activity is likely to be a
reliable measure of aggrecan degrading enzymes
in the medium since all MMPs including
MMP-3, and MMP-13 degrade aggrecan at the
MDIPEN4FFGVG locus [5, 19, 25].
The finding (Table I) that a small percentage of
the SP degrading MMP activity was not inhibited
with rTIMP, or BB2116 for CCM, but was totally
inhibited with metal chelators such as EDTA or
1,10-phenanthroline may be due to competitive
interactions of the rTIMP and BB2116 with other
components in the crude medium. It is also
conceivable that a small percentage of the calcium
dependent enzyme activity may be due to other
metal-dependent proteinases for example a soluble
membrane-type MMP [37].
We also considered the possibility of aggre-
canase activity contributing to SP cleavage. When
a peptide with the aggrecanase cleavage sequence
(NITEGE4ARGSVI) was used in the assay, there
was no cleavage of this peptide (data not shown).
Therefore, if aggrecanase is present in the media
from EOA tissue, its activity is not detectable
under these conditions.
An interesting finding in this study was that the
MMP-3 upregulation first appeared in the syn-
ovium at an early stage (4 weeks post-PM)
coincident with a mild transient inflammatory
response in this tissue and the appearance of
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superficial cartilage lesions, suggesting that
synovial tissue has a major role in the patho-
genesis of EOA in this model. This early-stage
upregulation may be due to the local production of
cytokines such as interleukin-1 (IL-1) in the
synovium. The production of MMP-3 in the
synovium at 4 weeks post-PM is likely to
contribute to cartilage degradation characterized
mainly by superficial erosions and pitting at this
time point.
In contrast, at 8 weeks when advanced cartilage
lesions characterized by increased ulcerations are
encountered, the synovial MMP-3 expression in
the controls is similar to that found in the medium
from EOA synovia. At the 8-week time-point the
chondrocyte-derived MMP activity was signifi-
cantly upregulated relative to the N controls; it did
not reach statistical significance relative to SH
controls. The reason for the latter is not clear; it
may be due to differences existing between
surgical controls and non-surgical controls be-
cause of the effects of surgery. Thus sham-surgery
appears to elicit certain tissue responses due to the
release of cytokines/factors from soft tissues
following surgical procedures. Although the re-
lease of tissue enzymes in SH knees is not enough
to cause cartilage degradation, it blunts the
comparison with PM rabbits, thus making the
levels statistically insignificant.
Of note was the finding that most of the enzyme
in both the CCMs and the SCMs were in an
activated form since further activation with
APMA resulted in only a marginal increase in
activity (if any). Therefore the enzyme is activated
in the medium prior to assay by activators also
synthesized and released by the chondrocytes and
the synovium.
The majority of the CCM did not contain
detectable levels of TIMP-1; a few contained very
low levels. This suggests that in this animal model
the synovium has a profound influence on the
pathologic degradation of cartilage by MMPs by
possibly regulating MMP and TIMP-1 levels. In
this regard it is interesting that TIMP-1 was
upregulated significantly only at 8 weeks post-PM,
a time point that corresponds to the progressive
stage of EOA, coincidental with upregulation of
MMP-3 in the cartilage. TIMP was not found to be
significantly elevated at 4 weeks post-PM when the
synovial enzyme pathway is upregulated. However,
since the ELISA assay used only measures free
TIMP, there may be MMP-TIMP complexes in
SCM at the 4 week time-point. Likewise, it is
possible that chondrocytes secrete small amounts
of TIMP that is bound by activated MMPs in the
medium, and thus not detected.
The finding that there was free TIMP-1 in the
SCMs together with active MMP-3 in the same
media is somewhat surprising. The reason for this
is not presently clear; it may be that the TIMP in
the medium had lost biological activity even
though it retained its antigenicity. An alternative
explanation could be that there may be an
inhibitory factor in the media that interferes with
binding of TIMP to the MMP. MMP-3 activity was
not fully inhibited even in the presence of high
concentrations (10 mg/ml) of exogenously added
TIMP suggesting that a portion of the MMP in the
medium is refractory to TIMP binding.
An interesting finding was a significant decrease
in the mean TIMP secretion by the N and the SH
synovium between the 4- and 8-week time-points
which is likely related to the maturation of the
animals. This curtailment in TIMP secretion may
be a contributory factor in the overall disease
pathophysiology, since by contrast, PM synovia
did not show a significant decrease in TIMP
output. This is expected since TIMP secretion by
EOA synovia is increased at 8 weeks post-PM, and
is in agreement with the differential upregulation
of TIMP relative to MMPs in OA [3, 27, 38].
Because the degradation of articular cartilage in
OA is a multi-component process with interplay of
multiple enzyme pathways each with its related
inhibition/activation mechanisms, it is difficult if
not impossible to dissect the processes in such a
way to study the behavior of one enzyme alone
in vivo or in tissue culture. Any substrate used may
be degraded by a group or family of related enzyme
activities such as the MMPs. Likewise, the use of
inhibitors such as TIMP or hydroxamate type
compounds to inhibit a certain MMP enzyme
pathway is not usually achievable because of the
broad specificity of such inhibitors towards all
MMPs. Also, it is possible that cultured chondro-
cytes or synovium may show alterations in MMP
and TIMP synthesis due to culturing. Relative to
this, we confirmed the presence of MMP-3 in fresh
frozen cartilage buffer extracts (data not shown),
suggesting that MMP-3 is synthesized in vivo.
Likewise, the amount of TIMP present in cultures
also may not best reflect the true concentrations in
vivo. To completely address the in vivo expression
of enzyme and TIMP, well-defined antibodies
would be required using quantitative immuno-
histochemical techniques.
Given the above caveats, we showed here that
metal-dependent proteinase activity with charac-
teristics of MMP-3 on the basis of substrate
specificity and inhibition with specific inhibitors is
secreted by EOA chondrocytes and synovium and
that its activity is upregulated at different time
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points in the progression of cartilage pathology. A
better understanding of cartilage degradation in
EOA as it pertains to human disease will be
achieved by purification and quantitation of
different MMPs from the media.
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